Follow on Google News News By Tag * Psoriasis * Treatment * Solution * Coal Tar * Plaque Psoriasis * Clinical Study * Lcd Solution * Psorent * Neostrata * Calcipitriol * More Tags... Industry News News By Place Country(s) Industry News
Follow on Google News | Psorent Solution Outperforms Calcipotriol In The Treatment Of Moderate PsoriasisNeoStrata announced findings from a 12-week study that demonstrates significant clinical benefits of a novel topically applied LCD (coal tar) solution (PsorentTM) versus calcipotriol cream (Dovonex®) in treatment of moderate plaque psoriasis.
By: NeoStrata Company The clinical data, from a trial conducted by investigator Alexa Kimball, MD, MPH, Massachusetts General and Brigham and Women’s Hospitals, Boston, are being written into a research article for publication next year. “These findings demonstrate the non-prescription LCD treatment Psorent outperformed a leading prescription medication thereby providing practitioners with a meaningful topical psoriasis treatment that is effective and well tolerated.” said Dr. Kimball. “Historically, tar has been considered unappealing due to its aesthetic profile, creating problems with patient compliance and overall satisfaction. This new formulation is aesthetically acceptable and was well-liked by the patients in the trial,” added Dr. Kimball. The 12-week study evaluated the safety and efficacy of the new topically applied 15% LCD against calcipotriol cream in treatment of 60 patients with moderate plaque psoriasis. The findings, representing final results for the 55 patients who had evaluable data, examined categorical and mean changes in PASI (Psoriasis Area Severity Index) improvement, as well as PGA (Physician’s Global Assessment) scores and patient self-assessment. Further data on file. Barbara Green, VP, Technology & Clinical Affairs, NeoStrata, said the study confirms their excitement about the efficacy and aesthetic appeal of Psorent, available from physicians without a prescription. In fact, 100% of patients found Psorent easy to use and nearly 90% said they would continue to use this treatment, citing that the dab-on applicator allowed them to apply the medication without touching the solution or their plaques. Patients also liked that the solution dried quickly, allowing them to get dressed soon after applying, and that this formulation reduced concerns of staining or mess. “The excellent patient satisfaction revealed in this study validates our success in creating this new-generation topical psoriasis therapy,“ said Ms. Green. “We developed Psorent to answer patient needs for clinical efficacy in an aesthetically pleasing non-prescription formulation that is different from the traditional coal tar experience. This formulation is quick-drying, has an acceptable scent, is easy to apply, and it works. We’re very pleased that we’ve been able to advance coal tar into the 21st century,” said Ms. Green. # # # NeoStrata Company, Inc. develops and markets advanced therapeutic and cosmetic dermatological products through consumer outlets and physicians' offices in the US, and internationally through physicians' offices, pharmacies and spas. End
Account Email Address Disclaimer Report Abuse
|
|